Aldeyra Therapeutics - ALDX Stock Forecast, Price & News

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Aldeyra Therapeutics Stock Up 6.9 %

ALDX traded up $0.48 during trading on Friday, reaching $7.47. The stock had a trading volume of 629,392 shares, compared to its average volume of 1,003,828. Aldeyra Therapeutics has a one year low of $2.36 and a one year high of $9.81. The company has a market capitalization of $435.65 million, a price-to-earnings ratio of -6.61 and a beta of 1.43. The company has a current ratio of 12.36, a quick ratio of 13.60 and a debt-to-equity ratio of 0.06. The stock's 50 day moving average is $4.67 and its two-hundred day moving average is $4.08.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Oppenheimer lifted their price objective on Aldeyra Therapeutics to $11.00 in a research report on Thursday, June 9th. Citigroup lifted their price target on shares of Aldeyra Therapeutics from $21.00 to $26.00 and gave the company a "buy" rating in a report on Thursday, June 9th. Berenberg Bank started coverage on shares of Aldeyra Therapeutics in a report on Tuesday, May 24th. They issued a "buy" rating and a $28.00 price objective for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $15.00 target price on shares of Aldeyra Therapeutics in a research note on Wednesday, July 13th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $19.00.

Insider Transactions at Aldeyra Therapeutics

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc purchased 15,000 shares of the stock in a transaction that occurred on Wednesday, August 10th. The stock was bought at an average cost of $7.85 per share, with a total value of $117,750.00. Following the transaction, the insider now directly owns 11,350,085 shares in the company, valued at approximately $89,098,167.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Todd C. Brady purchased 17,700 shares of Aldeyra Therapeutics stock in a transaction dated Thursday, June 23rd. The stock was purchased at an average cost of $3.36 per share, for a total transaction of $59,472.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,216,535 shares of the company's stock, valued at $4,087,557.60. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Perceptive Advisors Llc purchased 15,000 shares of the company's stock in a transaction that occurred on Wednesday, August 10th. The stock was purchased at an average price of $7.85 per share, for a total transaction of $117,750.00. Following the purchase, the insider now owns 11,350,085 shares in the company, valued at $89,098,167.25. The disclosure for this purchase can be found here. Insiders have acquired 497,600 shares of company stock valued at $2,803,640 in the last three months. 6.90% of the stock is currently owned by company insiders.